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Up to 30% of stage II patients with curatively resected colorectal cancer (CRC) will develop disease recurrence. We evaluated
whether examination of lymph nodes by multilevel sectioning and immunohistochemical staining can improve prognostication.
Lymph nodes (n 5 780) from 36 CRC patients who had developed disease recurrence (cases) and 72 patients who showed no
recurrence of disease for at least 5 years (controls) were analyzed. Sections of 4 levels at 200-lm interval were
immunohistochemically stained for cytokeratin expression. The first level was analyzed by conventional and automated
microscopy, and the 3 following levels were analyzed by automated microscopy for the presence of tumor cells. Overall, cases
showed more micrometastases (3 patients) than controls (1 patient). Analysis of a second level led to the additional detection
of 1 patient with micrometastases (case) and 1 patient with macrometastasis (case). Examining more levels only led to
additional isolated tumor cells, which were equally divided between cases and controls. Likewise, automated microscopy
resulted only in detection of additional isolated tumor cells when compared with conventional microscopy. In multivariate
analysis, micrometastases [odds ratio (OR) 26.3, 95% confidence interval (CI) 1.9–364.8, p 5 0.015], T4 stage (OR 4.8, 95%
CI 1.4–16.7, p 5 0.013) and number of lymph nodes (OR 0.9, 95% CI 0.8–1.0, p 5 0.028) were independent predictors for
disease recurrence. Lymph node analysis of 2 levels and immunohistochemical staining add to the detection of
macrometastases and micrometastases in CRC. Micrometastases were found to be an independent predictor of disease
recurrence. Isolated tumor cells were of no prognostic significance.
The presence of lymph node metastases is 1 of the most im-
portant prognostic factors in colorectal cancer (CRC) for which
adjuvant systemic chemotherapy is generally recommended.1–4
Patients with curatively resected stage I and II CRC without
nodal tumor involvement do not receive adjuvant systemic
therapy since only small improvements in survival have been
shown.4–6 However, 10–30% of these node-negative patients
will develop locoregional recurrence or distant metastases.1,7,8
Adjuvant systemic treatment of all node-negative CRC patients
is not recommended by the American Society of Clinical On-
cology as it would lead to overtreatment and unnecessary com-
plications.9 Identiﬁcation of node-negative CRC patients with a
high risk of disease recurrence may lead to a more appropriate
selection for adjuvant treatment.
Conventional histopathology has a limited sensitivity to
detect occult tumor cells in lymph nodes, described as micro-
metastases (>0.2 mm and 2 mm) and isolated tumor cells
(0.2 mm or single-tumor cells).10–12 Alternative approaches
to detect occult tumor cells in lymph nodes have been
reported such as: polymerase chain reaction,13 reverse tran-
scriptase polymerase chain reaction (RT-PCR),14 multilevel
sectioning,15 immunohistochemical staining16 and automated
microscopy.17 In a study published by Liefers et al.14 was
shown that stage II patients with carcinoembryonic antigen
(CEA) RT-PCR negative lymph nodes have a signiﬁcantly
better 5-year disease-related survival than patients with CEA
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RT-PCR positive lymph nodes (91 vs. 50%, p ¼ 0.02). These
results were conﬁrmed by several other groups.18–22
The detection of immunohistochemically stained tumor
cells has the advantage of visual examination of the detected
cells using microscopy. Multilevel sectioning and immunohis-
tochemistry have been shown to increase the detection rate
of lymph node metastases in CRC patients.13 Because screen-
ing of multiple immunohistochemically stained sections is
time consuming and difﬁcult to reproduce, automated mi-
croscopy has been implemented.17,23
In this case–control study, we evaluated whether detailed
examination of lymph nodes for the presence of occult tumor
cells by multilevel sectioning and immunohistochemical
staining can improve prognostication in CRC.
Material and Methods
Patient selection
Between January 1981 and December 2001, 1,044 patients
underwent surgery for a primary CRC at the Leiden University
Medical Center. For this study, a selection was made for
patients with negative lymph nodes (N0) and no metastases
(M0) at the time of surgery (n ¼ 506). Patients who were
operated on their ﬁrst CRC in another hospital or who were
diagnosed with another invasive malignancy before or within 5
years after the date of diagnosis of the primary colorectal carci-
noma, and patients who developed a local recurrence were
excluded for this study. The latter group was excluded to rule
out the factor of inadequate surgery. Cases (n ¼ 40) were
deﬁned as patients who had regional or distant recurrent dis-
ease at least 3 months after but within 5 years after the date of
diagnosis of primary CRC. Regional metastases were considered
intra-abdominal or intrapelvic metastases in lymph nodes or in
connective tissue. Thirty-six cases could be included in this
study, because lymph nodes from 4 cases could not be
retrieved from the archive. Controls (n ¼ 189) were patients
who did not develop locoregional or distant disease within 5
years after diagnosis of primary CRC. For each case, 2 controls
were matched for tumor-node-metastasis (TNM) stage, date of
incidence and date of birth, leading to a total number of 72
controls. The median follow-up of the case group was 2.5 years
(range, 5.3 months–6.3 years) and the median follow-up of the
control patient group was 10.8 years (range, 5.1–21.4 years).
Of 19 patients with rectal carcinoma, 2 patients had
received preoperative radiotherapy and 3 patients had
received postoperative radiotherapy. None of the patients had
received adjuvant chemotherapy.
Tissue specimens
After resection, the lymph nodes were ﬁxed in formalin,
processed through graded ethanol and embedded in parafﬁn
as part of a routine procedure for histopathological investiga-
tion. From 108 patients, a total of 780 lymph nodes were
harvested (median 6; range, 1–26 lymph nodes). The lymph
nodes were embedded in a total of 225 parafﬁn blocks.
Immunohistochemistry
For detection of tumor cells, a cocktail of murine monoclonal
antibodies AE1 and AE3 (Dako, Denmark) was used. AE1
recognizes cytokeratin 10, 13, 14, 15, 16 and 19, and AE3
recognizes cytokeratin 1, 2, 3, 4, 5, 6, 7 and 8. Four micron
sections were cut at 4 levels of each parafﬁn block with inter-
vals of 200 lm. The sections were situated on aminopropyle-
thoxysilane-coated slides and dried overnight at 37C. The
sections were subsequently deparafﬁnized in xylene, rehy-
drated and blocked for endogenous peroxidase in 0.3%
hydrogen peroxide/methanol at room temperature for 20
min. After washing in phosphate-buffered saline (PBS), anti-
gen retrieval treatment was performed by incubating the sec-
tions in a 0.01-M sodium citrate solution (pH 6.0) for 10
min at 100C. Then slides were rinsed twice in PBS, and the
primary antibody AE1/AE3 was applied at a 1:200 dilution in
PBS with 1% bovine serum albumine, respectively. The sec-
tions were incubated overnight at room temperature, washed
with PBS and incubated for 30 min with Envision-horserad-
ish peroxidase (Dako, Denmark). After 3 PBS washes and 1
rinse in 0.05 M Tris–HCl (pH 7.6), visualization of cytokera-
tin was achieved by incubation for 10 min with 3,30-diamino-
benzidinetetrachloride substrate in a buffered 0.05 M Tris–
HCl (pH 7.6) solution containing 0.002% hydrogen peroxide.
Sections were counterstained with Mayer’s hematoxylin and
dehydrated in graded ethanol followed by xylene and
mounted in glycerol. Cytokeratin-positive cells showed a
brown staining of the cytoplasm.
Additionally, we intended to analyze the 200-lm tissue of
parafﬁn-embedded lymph nodes between the sections used
for immunohistochemical staining by using RT-PCR. How-
ever, this was not feasible, because yield and quality of
extracted RNA was insufﬁcient (data not shown).
Analysis of the slides
All sections were analyzed using the ARIOL systemVR
(Applied Imaging a Genetix company). The features of the
ARIOL systemVR have been published previously.17 Sections
of the ﬁrst level were also analyzed by a pathologist (AML)
using conventional microscopy at a total magniﬁcation of
100 times. Selected candidate tumor cells were veriﬁed by the
operator and also visually conﬁrmed by an independent pa-
thologist (HM). Nonspeciﬁcally stained cells such as hemato-
poietic cells were visually recognized and excluded from the
analysis. Macrometastases were deﬁned as groups of cells
larger than 2 mm. Deposits of tumor cells of 2 mm or less
but larger than 0.2 mm were considered as micrometastases
and single-tumor cells or clusters of tumor cells of 0.2 mm
or less were classiﬁed as isolated tumor cells.10–12
Statistical analysis
Statistical analysis was carried out using SPSS software, ver-
sion 12.0.1 (SPSS, Chicago, IL). Numerical data are presented
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of skewness. The clinicopathologic features of cases and con-
trols were compared either by a Chi-square or Fisher’s exact
for categorical variables or by a Mann–Whitney or Student’s
t-test for numerical variables. Differences between screening
results by automated microscopy and conventional micros-
copy were analyzed by using the McNemar’s test. Univariate
and multivariate odds ratio’s (OR), 95% conﬁdence intervals
(95% CI) and p values (p) were calculated by applying logis-
tic regression analysis. A p value of less than 0.05 was consid-
ered an indication of statistical signiﬁcance. Variables with a
p value lower than 0.10 in the univariate analysis were
entered in the multivariate analysis. Because the number of
examined lymph nodes has been shown to be prognostically




Clinicopathologic characteristics of the patients are shown in
Table 1. No signiﬁcant differences in sex, T stage, tumor size,
tumor location, tumor differentiation, mucinous tumors, se-
rum CEA level and harvested lymph nodes [Mann–Whitney
test, median 6 (range, 1–18) vs. median 6 (range, 1–26), p ¼
0.096] were seen between the case and control group. If T2
and T3 stage were combined, more cases than controls were
staged as T4 than T2/3 [Fisher’s exact test, 8 of 36 (22%) vs.
6 of 72 (8%), p ¼ 0.066]. Except for T stage (T4 vs. T2/T3:
OR 3.1, 95% CI 1.0–9.9, p ¼ 0.050), the single-variable
regression analysis for disease recurrence of clinicopathologi-
cal parameters (Table 1) did not show any other signiﬁcant
risk factors. The single-variable regression analysis for the
Table 1. Patient and primary tumor characteristics (n ¼ 108)
Characteristics
Cases (n 5 36) Controls (n 5 72)
p1n % N %
Sex
Female 16 44 37 51 0.496
Male 20 56 35 49
Age (years)2 67 6 12 67 6 12 0.9113
TNM stage4
I 2 6 4 6 1.0005
II 34 94 68 94
T stage6
T2 2 6 4 6 0.126
T3 26 72 62 86
T4 8 22 6 8
Tumor size (cm) (n ¼ 104)2,7 4.9 6 1.9 (n ¼ 34) 5.2 6 2.1 (n ¼ 70) 0.5393
Tumor location
Colon (coecum–sigmoid) 30 83 59 82 0.858
Rectum (rectosigmoid–rectum) 6 17 13 18
Differentiation
Good 9 25 18 25 0.912
Moderate 22 61 46 64
Poor 5 14 8 11
Mucinous8
No 32 89 66 92 0.7285
Yes 4 11 6 8
Preoperative serum CEA level (n ¼ 43)9
<6 lg/l 5 56 25 74 0.4175
6 lg/l 4 44 9 26
Number of examined lymph nodes2 6.1 6 4.5 7.8 6 5.7 0.09610
CEA, carcinoembryonic antigen.
1Chi-square test of cases versus controls, unless mentioned otherwise. 2Presented as mean 6 standard deviation. 3Student t-test. 4According to the
6th edition of the TNM classiﬁcation.11 5Fisher’s exact test. 6If T2 and T3 stage were combined, the P-value was 0.043; this comparison was
therefore used in the logistic regression. 7Tumor size could not be found in pathology reports from 4 patients. 8A tumor was considered mucinous
when more than 50% of its volume existed of mucinous component. 9Serum CEA had been determined in only 43 of 108 patients as it was not a
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number of lymph nodes showed the following: OR 0.9, 95%
CI 0.9–1.0, p ¼ 0.132.
Multilevel sectioning, immunohistochemical staining
and automated microscopy
Analysis of the ﬁrst lymph node level identiﬁed micrometa-
stases in 3 (3%) patients (2 cases and 1 control) and isolated
tumor cells in 39 (37%) patients (13 cases and 26 controls)
(Table 2). One micrometastasis found in an immunohisto-
chemically stained section was also present on the original
Hematoxylin and eosin (HE) stained slide but was not recog-
nized by the pathologist. Macrometastases in 3 (3%) patients
(2 cases and 1 control) that had not been recognized as
lymph node metastases on the original HE stained slides
were also seen. They had been described as vascular invasion
or tumor deposits without lymphoid tissue in the pathology
reports. On the immunohistochemically stained slides of all
levels, lymphoid tissue was present around the tumor cells.
These macrometastases were excluded from further analysis.
All macrometastases and micrometastases were detected
by both conventional and automated microscopy. Automated
microscopy led to the detection of additional isolated tumor
cells (McNemar’s test, 39 vs. 10 patients, respectively, p <
0.001) (Table 3). All but 1 isolated tumor cell found by con-
ventional microscopy was also detected by automated micros-
copy. The missed isolated tumor cell was overlooked during
visual inspection of ARIOL system results by the operator.
Analysis of a second level, resulted in additional detection
of 1 patient with macrometastasis (a case), 1 patient with
micrometastases (a case) and 9 patients with isolated tumor
cells (2 cases and 7 controls) (Table 2). These patients had
no tumor cells detected in the ﬁrst level or in the original
HE-stained slide.
When analyzing a third level, 11 patients (3 cases and 8
controls) were additionally identiﬁed with isolated tumor
cells and assessment of a 4th level, identiﬁed 2 patients (2
controls) with isolated tumor cells. This led to a total number
of 61 patients with isolated tumor cells (Table 2). No addi-
tional macrometastases or micrometastases were found when
analyzing the 3rd and 4th level. In Figure 1, examples of
micrometastases (Figs. 1a and 1b) and isolated tumor cells
(Figs. 1c–1f) are shown.
Concluding, after analysis of 2 lymph node levels, macro-
metastases were observed in 1 patient (1 case) and microme-
tastases in 4 patients (3 cases and 1 control). Analysis of 2
additional lymph node levels solely identiﬁed the presence of
isolated tumor cells.
Prognostic signiﬁcance of lymph node metastases
More patients with micrometastases were seen in the case
group than in the control group (Fisher’s exact test, 3 of 34
(9%) vs. 1 of 71 (1%), p ¼ 0.099). There was no difference in
the presence of lymph nodes harboring isolated tumor cells,
between the case and control group (Chi-square test, 18 of
34 (53%) vs. 43 of 71 (61%), p ¼ 0.459) (Table 4). Separate
analysis of patients with colon carcinoma, rectal carcinoma,
right-sided or left-sided carcinoma did not result in signiﬁ-
cant difference in the presence of isolated tumor cells or per-
centage of lymph nodes harboring isolated tumor cells for
the case and control group. Neither did excluding patients
with T4 tumors or disregarding single-tumor cells as isolated
tumor cells.
From the clinicopathological variables, the T stage and the
number of examined lymph nodes were entered in the multi-
variate logistic regression analysis with the presence of micro-
metastases. These results showed that the presence of micro-
metastases (OR 26.3, 95% CI 1.9–364.8, p ¼ 0.015), a T4
stage (OR 4.8, 95% CI 1.4–16.7, p ¼ 0.013) and the number
of harvested lymph nodes (OR 0.9, 95% CI 0.8–1.0, p ¼
0.028) were independent predictors for disease recurrence.
When including the patient with macrometastasis detected
after analysis of a second level, the OR changed in favor of
the presence of macrometastases or micrometastases in
lymph nodes, showing the presence of macrometastases or
Table 2. Detection of tumor cells in parafﬁn-embedded lymph nodes from colorectal cancer patients (n ¼ 105) after multilevel sectioning1
and immunohistochemical staining combined with automated microscopy2
One level Two levels Three levels Four levels
n % n % n % n %
Lymph node status (n ¼ 772)
Macrometastases   1 0.1 1 0.1 1 0.1
Micrometastases 6 0.8 8 1.0 8 1.0 8 1.0
Isolated tumor cells 99 12.8 126 16.3 153 19.8 172 22.3
Patient status (n ¼ 105)
Macrometastases   1 1.0 1 1.0 1 1.0
Micrometastases 3 2.9 4 3.8 4 3.8 4 3.8
Isolated tumor cells 39 37.1 48 45.7 59 56.2 61 58.1
1Four micron sections were cut at 4 levels of each parafﬁn block with intervals of 200 lm. 2Patients with macrometastases in the ﬁrst lymph node
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Table 3. Detection of tumor cells in lymph nodes from colorectal cancer patients after immunohistochemical staining of the ﬁrst lymph node





n % n % n %
Lymph node status (n ¼ 772)
Macrometastases      
Micrometastases 6 0.8 6 0.8 6 0.8
Isolated tumor cells 15 1.9 99 12.8 1002 13.0
Patient status (n ¼ 105)
Macrometastases    
Micrometastases 3 2.9 3 2.9 3 2.9
Isolated tumor cells 10 9.5 39 37.1 39 37.1
1Patients with macrometastases in the ﬁrst lymph node level that had previously not been recognized as such, were excluded. 2One lymph node
with isolated tumor cells was missed by ARIOL automated microscopy.
Figure 1. Lymph node sections stained for cytokeratin by AE1/AE3 antibodies resulting in brown cells and counterstained using
hematoxylin and eosin. Micrometastases (>0.2 mm and 2 mm) at a magniﬁcation of 125 (a) and 250 (b); isolated tumor cells (tumor
cell clusters  0.2 mm) at a magniﬁcation of 125 (c) and 500 (d); isolated tumor cells (single cells) at a magniﬁcation of 250 (e) and
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micrometastases (OR 34.5, 95% CI 2.7–440, p ¼ 0.006), a T4
stage (OR 2.9, 95% CI 0.4–23.5, p ¼ 0.040) and the number
of examined lymph nodes (OR 0.9, 95% CI 0.8–1.0, p ¼
0.025) to be independent predictors for disease recurrence.
Relation between lymph node metastases and
clinicopathological features
There was no correlation observed for the presence of micro-
metastases in lymph nodes and patient’s gender, tumor loca-
tion, tumor size, T-stage, TNM stage and serum CEA level
(all p > 0.05). In rectal carcinoma, fewer lymph nodes were
harvested than in colon carcinoma (Mann–Whitney test; me-
dian 3; range, 1–13 vs. median 7; range, 1–26; p ¼ 0.037).
Also, patients with less than 12 harvested lymph nodes were
signiﬁcantly older than patients with 12 or more harvested
lymph nodes (Student’s t-test, 69 6 10 vs. 61 6 15, p ¼
0.008). No difference was seen in the number of lymph nodes
harvested for the different T stages.
Discussion
In this study, we analyzed parafﬁn-embedded lymph nodes
from patients with CRC by using multilevel sectioning com-
bined with immunohistochemical staining and demonstrated
that the presence of micrometastases was an independent
predictor for disease recurrence. Analysis of a second lymph
node level led to detection of additional prognostically rele-
vant macrometastases and micrometastases. Examination of
more levels and the use of automated microscopy led to
detection of additional isolated tumor cells, which were prog-
nostically not relevant.
We performed this study, because the prognostic signiﬁ-
cance of occult tumor cells in lymph nodes in CRC is still a
matter of debate. A meta-analysis showed that immunohisto-
chemical detection of occult tumor cells combined with serial
or multilevel sectioning led to upstaging of 32% of previously
considered node-negative patients, but the presence of occult
tumor cells did not lead to a statistically signiﬁcant adverse
clinical outcome.25 The meta-analysis reported an upstaging
of 37% by RT-PCR and in contrast to immunohistochemistry
studies, most RT-PCR studies found the presence of occult
tumor cells in lymph nodes to predict a worse clinical out-
come (overall 3-year survival of 78% vs. 97%, p <
0.001).13,14,18-22,25 However, although several alternative tech-
niques are evaluated for improving RNA yield,26,27 optimal
results with RT-PCR are mainly achieved when using fresh
frozen tissue.28,29 This is more laborious and lacks morpho-
logical assessment. Therefore, serial or multilevel sectioning
combined with immunohistochemical staining is preferred,
because it can be reliably used on parafﬁn-embedded tissue
and the morphology of stained cells can be examined.
The fact that most immunohistochemistry studies show
no difference in clinical outcome between patients with
lymph nodes containing occult tumor cells and patients with
tumor-negative lymph nodes, we ascribe to the lack of mak-
ing a distinction between micrometastases and isolated tumor
cells.13,30–37 The last 6th TNM edition11,12 recommends clas-
sifying occult tumor cells in lymph nodes into micrometasta-
ses and isolated tumor cells. According to this TNM edition,
isolated tumor cells in lymph nodes, which are less than 0.2
mm in diameter, are insigniﬁcant and should be classiﬁed as
pN0(iþ). Lymph-node deposits with a diameter between 0.2
and 2 mm should be classiﬁed as micrometastases (mi) and
staged as node-positive pN1(mi). Even so, this recommenda-
tion, published in 2002, was not based on evidence but more
on logical reasoning. In our study, isolated tumor cells were
found of no clinical relevance and do conﬁrm the guidelines
of the TNM classiﬁcation system. Only 2 other research
groups29,38 have previously published study results regarding
CRC patients in which they differentiated between microme-
tastases and isolated tumor cells, emphasizing the importance
of our study. Messerini et al.38 examined lymph nodes from
395 stage IIA CRC patients by immunohistochemical staining
of 12 serial sections with antibodies directed against cytokera-
tin 20. Micrometastases were detected in lymph nodes from
9.9% of the patients, and isolated tumor cells were seen in
28.4% of patients. Similar to our ﬁndings, they did not ﬁnd
prognostic relevance of isolated tumor cells and showed a
lower survival rate in patients with micrometastases com-
pared to patients with isolated tumor cell-positive and tu-
mor-negative lymph nodes. We suggest that the lack of prog-
nostic signiﬁcance of isolated tumor cells might be explained
by assuming that these cells are shed from the primary tumor
Table 4. Clinical relevance of occult tumor cells in lymph nodes from patients with colorectal cancer (n ¼ 105)1
Lymph node status
Cases (n 5 34) Controls (n 5 71)
p2n % n %
Tumor-positive 22 65 44 62 0.786
Macrometastases 1 3 0 0 0.3243
Micrometastases 3 9 1 1 0.0993
Isolated tumor cells 18 53 43 61 0.459
Cases were deﬁned as patients who had regional or distant disease recurrence within 5 years after the date of diagnosis of primary colorectal
cancer; Controls were patients who did not develop locoregional or distant disease within 5 years after diagnosis of primary colorectal cancer.
1Patients with macrometastases in the ﬁrst lymph node level that had not been previously recognized as such, were excluded. 2Chi-square test of
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and transported through lymphatic vessels to the lymph
nodes, but do not have the potential of independent outgrow
and, therefore, do not form established metastases. The sec-
ond research group29 who made a distinction between micro-
metastases and isolated tumor cells in CRC, examined 2
lymph node levels at a 200-lm interval with antibodies AE1/
AE3. They detected micrometastases in 7 of 234 patients
(3%), which correspond to the detection rate in our patient
group. This group did not evaluate the prognostic relevance
of micrometastases in CRC leaving only 2 studies by Messer-
ini et al.38 and our study who did.
Although we choose for a case–control design, because
this was more cost-effective than a retrospective cohort
study, our study has advantages such as reliable follow-up
of the patients by our Department of Oncological Docu-
mentation and the matching of 2 controls for each case. A
limitation of our study, which is known when evaluating
archival material for research purposes, was the infeasibility
to select for patients with at least 12 lymph nodes examined
for accurate staging as recommended by the American Joint
Committee on Cancer Staging12 and the International
Union against Cancer.11 Twenty percent of our patient
group underwent an adequate lymph node harvest of at
least 12 lymph nodes. Other studies examining large
archival material also demonstrated this limitation. Only
22% of 569 CRC specimens studied by Johnson et al.39 and
37% of 116,995 CRC patients in a study by Baxter et al.40
received adequate evaluation of 12 or more lymph nodes.
Factors that have been reported to affect the number of
lymph nodes retrieved in CRC specimens were the effect of
different pathology assistants, older age, rectal cancer and
the T stage.40–42 We also saw less patients with a harvest of
at least 12 lymph nodes in rectal carcinoma than in colon
carcinoma, and patients with at least 12 lymph nodes har-
vested were signiﬁcantly younger than patients with less
than 12 lymph nodes harvested. Even so, evidence exists
that the number of harvested lymph nodes has increased
during the last 2 decades. In our group, an RT-PCR study
regarding detection of occult tumor cells in lymph nodes
from 26 CRC patients who were included from January
1990 and February 1992 has been previously published.14 In
this study, 246 lymph nodes were freshly isolated leading to
an average of 9.5 compared to an average of 7.2 in our pres-
ent study in which lymph nodes were isolated after ﬁxation
in formalin. Experience in our pathology laboratory has
shown that more lymph nodes are harvested when isolated
freshly than when harvested after formalin ﬁxation (data
not published). Also, in a prospective sentinel lymph node
study, in CRC patients29 between 1996 and 2001, more
lymph nodes were harvesting in the study group (average
14) than in the control group (average 10), suggesting that
more lymph nodes are harvesting within a trial design. Fat
clearance techniques increases the number of harvested
lymph nodes, especially small lymph nodes less than 5
mm.43,44 However, these methods are time consuming, ex-
pensive and impractical as they involve noxious volatile
agents.
Nevertheless, in our study, the number of examined
lymph nodes was included in the multivariate analysis and
in line with the literature, we found that a lower number
of examined lymph nodes was an independent risk factor24
for disease recurrence together with T4 stage and the pres-
ence of micrometastases. Because detailed analysis of
lymph nodes using serial or multilevel sectioning and
immunohistochemistry is costly and time- and labor-con-
suming, we should take into account restriction of lymph
node sampling or ultrastaging of sentinel lymph node(s),
which have the highest risk for harboring metastases. In a
recent study by Pusztaszeri et al.,42 the value of sampling
lymph nodes located at distance sidelong CRC specimens
was assessed. Mesocolic and perirectal fat were divided
into 2 fractions: close to (<5 cm) and distant from (>5
cm) from the primary tumor. They found that in the co-
lon, lymph node location is more important than lymph
node number, because metastatic lymph nodes were pres-
ent mostly in the peritumoral area. This suggested that
lymph nodes should be initially recovered from the peri-
colic fat close to the tumor. If there are less than 4 tumor-
positive lymph nodes and less than 12 tumor-negative
lymph nodes examined in total, only then additional
lymph nodes should be retrieved from the distal fraction
for potential upstaging. In the rectum, systematic sampling
of close and distant lymph nodes seemed mandatory,
because, in some cases, metastases were detected only in
distant lymph nodes, particularly in patients who had
undergone neoadjuvant radiotherapy.
Additionally, interim results from Bilchik et al.45 assess-
ing sentinel lymph nodes for the presence of occult tumor
cells, suggests the presence of micrometastases in sentinel
lymph nodes to increase the risk for disease recurrence.
Importantly, quantitative restriction of lymph node sam-
pling and sentinel lymph node mapping in CRC does not
substitute a complete oncologic resection and thus far all
lymph nodes will continued to be examined with conven-
tional HE staining.
In conclusion, there is need for better prognostication in
stage II CRC patients, because disease recurrence will occur
in up to 30% of these patients, and the administration of ad-
juvant chemotherapy to all node negative CRC patients is
controversial. Our study results show that immunohisto-
chemistry combined with two-level analyses of lymph nodes
is helpful in detecting macrometastases and micrometastases,
which showed prognostic relevance. Isolated tumor cells were
of no prognostic importance.
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